fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2006-09-18 Cell Therapeutics (USA)
Novartis
Xyotax® (poliglumex paclitaxel) - Xyotax® is paclitaxel linked to a biodegradable polymer / non-small-cell lung cancer licensing
development
See details
2006-09-12 NascaCell Technologies (Germany)
AstraZeneca (GB)
aptamers /   R&D
See details
2006-09-07 Trimeris (USA)
Roche (Switzerland)
fusion inhibitors / AIDS R&D
See details
2006-09-07 Graffinity (Germany)
Boehringer Ingelheim (Germany)
  R&D
other
See details
2006-07-27 Kinaxo Biotechnologies (Germany)
Schering AG (Germany)
Kinator® technology
(This technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples)
R&D
other
See details
2006-07-25 Santaris Pharma (Denmark)
Enzon (USA)
RNA antagonists (8 preclinical molecules including a HIF-1 alpha antagonist (SPC2968) and an antagonist of the survivin anti-apoptosis protein (SPC3042) / cancer commercialization/ distribution
development
See details
2006-07-25 Genentech (USA)
Inotek (USA)
 
inhibitors of PARP (poly (ADP-ribose) polymerase) / cancer R&D
commercialization/ distribution
See details
2006-07-13 CeNes(UK), Ergomed (Germany)
 
CNS 5161 (NMDA receptor antagonist) / neuropathic pain associated with diabetes and pain in cancer patients. development
See details
2006-06-22 greenovation Biotech GmbH (Germany)
Bayer Innovation (Germany)
control and improvement thanks to better understanding of (i) the mechanisms of protein glycosylation in plants and (ii) the activity and bioavailability of therapeutic proteins produced in plants. /   other
See details
2006-06-13 Intercell (Austria)
Novartis (Switzerland)
vaccine IC51 / Japanese encephalitis commercialization/ distribution
See details
2006-06-07 Galapagos (Belgium)
GSK (UK)
/ osteoarthritis R&D
See details
2006-05-22 TcLand (France)
Debiopharm (Switzerland)
fusion protein (sc28AT protein ?CD28 antagonist) / graft rejection and autoimmune diseases R&D
See details
2006-05-17 Morphosys (Germany)
Schering-Plough (USA)
HuCAL GOLD® technology licensing
See details
2006-05-10 Immunomedics (USA)
UCB (Belgium)
epratuzumab / autoimmune diseases other
See details
2006-05-08 Borean Pharma (Denmark)
Roche (Switzerland)
Trimeric Apo A-I (a modified version of apolipoprotein A-I) / cardiovascular disease commercialization/ distribution
development
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]